AsiaPharm Of China, GlycoMar Of Scotland In R&D Tie
This article was originally published in PharmAsia News
China's AsiaPharm and GlycoMar, a biotech based in Scotland, have signed an agreement to conduct research and development for drugs based on marine glycomolecules. The agreement was reached as AsiaPharm, based in Shanghai, faces a takeover bid by MBK Partners, a Korean private-equity firm. Under the agreement with GlycoMar, the Scottish firm is to supply purified marine glycans to AsiaPharm to be studied for possible drug applications. The companies would collaborate on any candidates that result. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.